Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden.
Breast cancer
Metachronous cancer
Oncogenesis
Thyroid cancer
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Jun 2021
15 Jun 2021
Historique:
received:
25
10
2020
accepted:
18
05
2021
entrez:
16
6
2021
pubmed:
17
6
2021
medline:
21
10
2021
Statut:
epublish
Résumé
Epidemiological evidence suggests that synchronous or metachronous presentation of breast and thyroid cancers exceeds that predicted by chance alone. The following potential explanations have been hypothesized: common environmental or hormonal factors, oncogenic effect of the treatment for the first cancer, closer follow-up of cancer survivors, shared underlying genetic risk factors. While some cases were found to be related to monogenic disorders with autosomal inheritance, the genetic background of most cases of co-occurring breast and thyroid cancer is thought to be polygenic. In this retrospective case-control study we compared the genetic profile of patients with a history of breast cancer (n = 15) to patients with co-occurring breast and thyroid cancer (n = 19) using next generation sequencing of 112 hereditary cancer risk genes. Identified variants were categorized based on their known association with breast cancer and oncogenesis in general. No difference between patients with breast and double cancers was observed in clinical and pathological characteristics or the number of neutral SNPs. The unweighted and weighted number of SNPs with an established or potential association with breast cancer was significantly lower in the group with breast cancer only (mean difference - 0.58, BCa 95% CI [- 1.09, - 0.06], p = 0.029, and mean difference - 0.36, BCa 95% CI [- 0.70, - 0.02], p = 0.039, respectively). The difference was also significant when we compared the number of SNPs with potential or known association with any malignancy (mean difference - 1.19, BCa 95% CI [- 2.27, - 0.11], p = 0.032 for unweighted, and mean difference - 0.73, BCa 95% CI [- 1.32, - 0.14], p = 0.017 for weighted scores). Our findings are compatible with the hypothesis of genetic predisposition in the co-occurrence of breast and thyroid cancer. Further exploration of the underlying genetic mechanisms may help in the identification of patients with an elevated risk for a second cancer at the diagnosis of the first cancer.
Sections du résumé
BACKGROUND
BACKGROUND
Epidemiological evidence suggests that synchronous or metachronous presentation of breast and thyroid cancers exceeds that predicted by chance alone. The following potential explanations have been hypothesized: common environmental or hormonal factors, oncogenic effect of the treatment for the first cancer, closer follow-up of cancer survivors, shared underlying genetic risk factors. While some cases were found to be related to monogenic disorders with autosomal inheritance, the genetic background of most cases of co-occurring breast and thyroid cancer is thought to be polygenic.
METHODS
METHODS
In this retrospective case-control study we compared the genetic profile of patients with a history of breast cancer (n = 15) to patients with co-occurring breast and thyroid cancer (n = 19) using next generation sequencing of 112 hereditary cancer risk genes. Identified variants were categorized based on their known association with breast cancer and oncogenesis in general.
RESULTS
RESULTS
No difference between patients with breast and double cancers was observed in clinical and pathological characteristics or the number of neutral SNPs. The unweighted and weighted number of SNPs with an established or potential association with breast cancer was significantly lower in the group with breast cancer only (mean difference - 0.58, BCa 95% CI [- 1.09, - 0.06], p = 0.029, and mean difference - 0.36, BCa 95% CI [- 0.70, - 0.02], p = 0.039, respectively). The difference was also significant when we compared the number of SNPs with potential or known association with any malignancy (mean difference - 1.19, BCa 95% CI [- 2.27, - 0.11], p = 0.032 for unweighted, and mean difference - 0.73, BCa 95% CI [- 1.32, - 0.14], p = 0.017 for weighted scores).
CONCLUSION
CONCLUSIONS
Our findings are compatible with the hypothesis of genetic predisposition in the co-occurrence of breast and thyroid cancer. Further exploration of the underlying genetic mechanisms may help in the identification of patients with an elevated risk for a second cancer at the diagnosis of the first cancer.
Identifiants
pubmed: 34130653
doi: 10.1186/s12885-021-08377-4
pii: 10.1186/s12885-021-08377-4
pmc: PMC8207626
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
706Subventions
Organisme : Ministry for Innovation and Technology, Hungary
ID : 2020-4.1.1.-TKP2020
Références
J Cancer Res Ther. 2015 Oct-Dec;11(4):684-9
pubmed: 26881502
Cancer Epidemiol Biomarkers Prev. 2016 Feb;25(2):231-8
pubmed: 26908594
Oncogene. 2002 Jun 20;21(27):4307-16
pubmed: 12082618
Med Sci Monit. 2015 Jan 22;21:283-91
pubmed: 25612155
Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):643-649
pubmed: 30541751
Am Soc Clin Oncol Educ Book. 2015;:e66-73
pubmed: 25993238
Cancer Lett. 1994 Aug 29;84(1):59-66
pubmed: 7521273
J Clin Endocrinol Metab. 2008 Feb;93(2):504-15
pubmed: 18029468
Hum Mol Genet. 2012 Jan 15;21(2):300-10
pubmed: 21979946
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Cancer Causes Control. 2009 Jul;20(5):525-31
pubmed: 19016336
Thyroid. 2015 Dec;25(12):1330-8
pubmed: 26442580
Front Endocrinol (Lausanne). 2017 May 23;8:111
pubmed: 28588554
Cancer. 2005 Mar 15;103(6):1122-8
pubmed: 15712375
Cancer Causes Control. 2000 Oct;11(9):805-11
pubmed: 11075869
J Endocrinol Invest. 2017 Oct;40(10):1035-1047
pubmed: 28516372
Endocrinology. 2016 Aug;157(8):3278-92
pubmed: 27253998
Eur J Surg Oncol. 2018 Mar;44(3):307-315
pubmed: 28343733
JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22
pubmed: 24557566
Oncology. 1999;56(1):43-5
pubmed: 9885376
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Annu Rev Genomics Hum Genet. 2017 Aug 31;18:201-227
pubmed: 28504904
N Engl J Med. 2014 Nov 6;371(19):1765-7
pubmed: 25372084
Endocr Rev. 2015 Dec;36(6):E1-E150
pubmed: 26544531
Surgery. 2016 Jan;159(1):23-9
pubmed: 26522696
Med Hypotheses. 2019 Jan;122:5-7
pubmed: 30593422
J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):57-66
pubmed: 18328691
Eur J Endocrinol. 2006 Dec;155(6):801-6
pubmed: 17132748
Cell. 2018 Aug 9;174(4):1034-1035
pubmed: 30096302
Semin Oncol. 2003 Dec;30(6):740-8
pubmed: 14663775
J Clin Oncol. 2014 Jun 10;32(17):1818-24
pubmed: 24778394
Radiother Oncol. 2016 Dec;121(3):402-413
pubmed: 27639892
N Engl J Med. 2008 Nov 13;359(20):2143-53
pubmed: 19005198
Eur Thyroid J. 2017 Jul;6(4):197-207
pubmed: 28868260
Thyroid. 2010 Jan;20(1):33-41
pubmed: 20067378
J Clin Endocrinol Metab. 2008 Mar;93(3):809-14
pubmed: 18160464
Environ Int. 2017 Oct;107:235-242
pubmed: 28772138
Cancer Res. 2009 Jan 15;69(2):501-9
pubmed: 19147563
Thyroid. 2009 May;19(5):451-7
pubmed: 19281429
Biochim Biophys Acta. 2013 Jul;1830(7):3928-36
pubmed: 22507269
Nucl Med Commun. 2016 Feb;37(2):110-5
pubmed: 26513055
Breast Cancer Res Treat. 2012 Jun;133(3):1169-77
pubmed: 22434524
Breast Cancer Res Treat. 2015 Jul;152(1):173-181
pubmed: 26058757
Thyroid. 2012 Jan;22(1):53-8
pubmed: 22142373
Ann Surg Oncol. 2012 Jun;19(6):1887-96
pubmed: 22227921
Cancer. 2001 Sep 15;92(6):1411-8
pubmed: 11745217
J Natl Cancer Inst. 1994 Nov 2;86(21):1600-8
pubmed: 7932824
Cancer Res. 1987 Jan 1;47(1):292-5
pubmed: 3791213
Asian Pac J Cancer Prev. 2014;15(16):6643-7
pubmed: 25169502
Basic Clin Pharmacol Toxicol. 2008 Feb;102(2):125-33
pubmed: 18226065